Drugs / NWRD06
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06088459 | Nov 2023 → Dec 2024 | hepatocellular carcinoma | Newish Technology (Beijing) Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07324304 | Dec 2025 → Dec 2028 expected | hepatocellular carcinoma | Newish Technology (Beijing) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NWRD06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07324304 ↗ |
| Modality | Vaccine | “Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06)” NCT06088459 ↗ |
| Route | Intramuscular | “DNA plasmid delivered via IM injection + electroporation using TERESA device” NCT06088459 ↗ |
| Target | GPC3 | “Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06)” NCT06088459 ↗ |